ARCHIVES

Cephalon To Plead Guilty, Pay $425M For Off-Label Marketing.

This article is from The Cancer Letter archive.

Vol. 34 No. 36 | October 3, 2008

Download PDF Visit The Full Archive

Related Articles

Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation

August 29, 2014

UICC Announces Four Grant award Programs

July 14, 1978

PLCO Data Confirm Importance Of Regular Colorectal Cancer Screening, NCI Says

July 25, 2003

House, Senate Must Resolve Major Differences In Authorization Bills

September 12, 1980

In Brief: Commerce Dept. Open Radiation Standards Facility For Mammography Calibration

April 4, 1996

Nexavar Improves PFS In Phase III Trial

January 25, 2013